Securities code: 000661 securities abbreviation: Changchun High And New Technology Industries (Group) Inc(000661) Announcement No.: 2022-004 Changchun High And New Technology Industries (Group) Inc(000661) technology industry (Group) Co., Ltd
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Changchun High And New Technology Industries (Group) Inc(000661) technology industry (Group) Co., Ltd. (hereinafter referred to as “the company”) shares (securities code: 000661, securities abbreviation: Changchun High And New Technology Industries (Group) Inc(000661) ) within three consecutive trading days (January 19, 2022, January 20, 2022, January 21, 2022), the deviation value of daily closing price rise and fall has reached – 20%. According to the relevant regulations of Shenzhen Stock Exchange, It belongs to abnormal fluctuation of stock trading.
2、 The company pays attention to and verifies relevant information
In view of the abnormal fluctuation of the company’s shares, the company has verified the relevant matters, and the relevant information is described as follows:
1. Recently, investors have paid more attention to the documents related to centralized drug procurement in Guangdong Province, which are verified by the company as follows:
On January 19, 2022, Guangdong Pharmaceutical Trading Center issued the document on centralized procurement of diclofenac and other drugs of Guangdong alliance. According to the relevant documents in Schedules 1, 2 and 3 of the document, the company’s subsidiary Changchun Kinsey Pharmaceutical Co., Ltd. (hereinafter referred to as “Kinsey pharmaceutical”) recombinant human growth hormone for injection and recombinant human growth hormone injection have been included in the scope of centralized procurement in the alliance area.
At present, the bidding procedure for the centralized drug procurement has not been officially started, and the specific impact on the company’s performance will also depend on the actual participation in bidding, winning results and winning prices of Kinsey pharmaceutical. The impact and degree of this centralized procurement on the company have not been determined. The company and Kinsey pharmaceutical will formulate relevant plans based on the practical maintenance of the company’s interests without violating laws and regulations.
In addition, the company has not found any other major events that may have a great impact on the company’s share price.
2. With regard to the pledge of the shares of the controlling shareholders of the company, after confirmation with the pledgor and the indirect controlling shareholders of the company, Longxiang Investment Holding Group Co., Ltd. and Changchun New Area Development Group Co., Ltd., the relevant shareholders will take supplementary guarantee measures such as supplementary property mortgage, supplementary guarantee and prepayment to ensure that the mortgagee will not take the means of closing positions.
The State-owned Assets Supervision Department of Changchun new area will also pay close attention to the relevant situation to avoid risks.
3. At present, the production and operation of the company and its branches and subsidiaries are normal, the team is stable, and the internal and external business environment has not changed significantly.
4. The company held the 7th Meeting of the 10th board of directors on November 23, 2021, deliberated and adopted the proposal on share repurchase scheme of the company. At present, the repurchase plan has been implemented.
5. The company did not find that the information disclosed in the previous period needed to be corrected and supplemented.
6. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that, in addition to the above matters, the company has no undisclosed matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange or planning, negotiation, intention, agreement, etc. related to the matters; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and has a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
1. After self-examination, the company does not violate the fair disclosure of information.
2. At present, the company’s business data in 2021 is in the process of statistics. If there are relevant circumstances specified in the stock listing rules of Shenzhen Stock Exchange after preliminary accounting by the company’s financial department, the company will issue performance forecast in accordance with the regulations. The company’s performance information in 2021 is not provided to any third party other than the accounting firm audited by the company.
3. The company solemnly reminds investors: securities times, China Securities News and cninfo (www.cn. Info. Com. CN.) For the information disclosure media selected by the company, all information of the company shall be subject to the information disclosed in the above media. Investors are invited to invest rationally and pay attention to risks.
It is hereby announced.
Board of directors of Changchun High And New Technology Industries (Group) Inc(000661) technology industry (Group) Co., Ltd
January 24, 2022
